Spyre Therapeutics launched SPY772 and started the SKYLIGHT Phase 2 trial in hidradenitis suppurativa. The study will test proof of concept for TL1A and IL-17A/

BWB News TV • 2026-08-10 12:26 UTC • By Billy Odell Tucker-Robinson

Spyre Therapeutics launched SPY772 and started the SKYLIGHT Phase 2 trial in hidradenitis suppurativa. The study will test proof of concept for TL1A and IL-17A/F inhibition in a chronic skin disease with limited treatment options.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly